These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28066307)

  • 1. Illness Representations of HIV Positive Patients Are Associated with Virologic Success.
    Leone D; Borghi L; Lamiani G; Barlascini L; Bini T; d'Arminio Monforte A; Vegni E
    Front Psychol; 2016; 7():1991. PubMed ID: 28066307
    [No Abstract]   [Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
    Robbins GK; Cohn SE; Harrison LJ; Smeaton L; Moran L; Rusin D; Dehlinger M; Flynn T; Lammert S; Wu AW; Safren SA; Reynolds NR
    HIV Clin Trials; 2016 Jul; 17(4):165-72. PubMed ID: 27347650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.
    Pence BW; Miller WC; Gaynes BN; Eron JJ
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):159-66. PubMed ID: 17146374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
    Tuldrà A; Fumaz CR; Ferrer MJ; Bayés R; Arnó A; Balagué M; Bonjoch A; Jou A; Negredo E; Paredes R; Ruiz L; Romeu J; Sirera G; Tural C; Burger D; Clotet B
    J Acquir Immune Defic Syndr; 2000 Nov; 25(3):221-8. PubMed ID: 11115952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China.
    Wang X; Yang L; Li H; Zuo L; Liang S; Liu W; Dong Y; Yang S; Shang H; Li J; Kang L; Zhong P; Zheng W; Liao L; Xing H; Chen RY; Ruan Y; Shao Y
    Curr HIV Res; 2011 Mar; 9(2):103-11. PubMed ID: 21361864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].
    Alave J; Paz J; González E; Campos M; Rodríguez M; Willig J; Echevarría J
    Rev Chilena Infectol; 2013 Feb; 30(1):42-8. PubMed ID: 23450408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
    Silveira MP; Maurer P; Guttier MC; Moreira LB
    J Clin Pharm Ther; 2015 Apr; 40(2):192-5. PubMed ID: 25422132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
    Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
    AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing illness representations and perceived adherence in haemophilic patients: a pilot study.
    Lamiani G; Strada I; Mancuso ME; Coppola A; Vegni E; Moja EA;
    Haemophilia; 2015 Sep; 21(5):598-604. PubMed ID: 25684356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania.
    Ramadhani HO; Thielman NM; Landman KZ; Ndosi EM; Gao F; Kirchherr JL; Shah R; Shao HJ; Morpeth SC; McNeill JD; Shao JF; Bartlett JA; Crump JA
    Clin Infect Dis; 2007 Dec; 45(11):1492-8. PubMed ID: 17990233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.
    Blacher RJ; Muiruri P; Njobvu L; Mutsotso W; Potter D; Ong'ech J; Mwai P; Degroot A; Zulu I; Bolu O; Stringer J; Kiarie J; Weidle PJ
    AIDS Care; 2010 Nov; 22(11):1323-31. PubMed ID: 20711886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment of Youth Living With HIV to Optimize Adherence and Virologic Suppression: Testing the Design of Technology-Based Community Health Nursing to Improve Antiretroviral Therapy (ART) Clinical Trials.
    Agwu AL; Yusuf HE; D'Angelo L; Rathore M; Marchesi J; Rowell J; Smith R; Toppins J; Trexler C; Carr R; Johnson B; Selden AK; Mahmoudi S; Black S; Guadamuz J; Huettner S; Trent M
    JMIR Res Protoc; 2020 Dec; 9(12):e23480. PubMed ID: 33306036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
    Chung MH; Richardson BA; Tapia K; Benki-Nugent S; Kiarie JN; Simoni JM; Overbaugh J; Attwa M; John-Stewart GC
    PLoS Med; 2011 Mar; 8(3):e1000422. PubMed ID: 21390262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.
    Maggiolo F; Airoldi M; Kleinloog HD; Callegaro A; Ravasio V; Arici C; Bombana E; Suter F
    HIV Clin Trials; 2007; 8(5):282-92. PubMed ID: 17956829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.
    Hart JE; Jeon CY; Ivers LC; Behforouz HL; Caldas A; Drobac PC; Shin SS
    J Acquir Immune Defic Syndr; 2010 Jun; 54(2):167-79. PubMed ID: 20375848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic success in an urban HIV clinic: outcome at 12 months in patients who were HAART naïve.
    Blanchard E; Klibanov OM; Axelrod P; Palermo B; Samuel R
    HIV Clin Trials; 2008; 9(3):186-91. PubMed ID: 18547905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.